Danaher Corporation (NYSE:DHR) delivered second-quarter results on July 21, marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Despite beating earnings estimates, raising its adjusted EPS guidance, and reporting improving trends in its Life Sciences business, investors remain unconvinced following weaker-than-expected bioprocessing revenue and a reduction in its full-year core revenue growth outlook.
The mixed results raise an important question for investors: Is Danaher Corporation’s (NYSE:DHR) recent weakness creating a buying opportunity, or are growth concerns beginning to outweigh its long-term strengths?
Bull Case
One of the biggest positives from the quarter was Danaher Corporation’s (NYSE:DHR) Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs.
Danaher Corporation (NYSE:DHR) stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This distinction matters because it suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth. While the academic and government markets have largely stabilized, more supportive government policies would be essential to safely call it an inflection point.
Key fiscal Q2 2026 results included a 5.5% year-over-year growth in revenue to $6.3 billion, as well as a 60% year-over-year rise in net earnings to $870 million, or $1.23 per diluted common share. The company also reported that non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue, excluding respiratory testing revenue, increased 4.5% year-over-year, suggesting improving trends in the company’s operations. According to data compiled by LSEG, Danaher Corporation (NYSE:DHR) profits for the quarter reached $1.94 per share, above estimates of $1.83 per share.
Bear Case
On the other hand, Danaher Corporation (NYSE:DHR) reported weaker-than-expected revenue in its biotechnology business and cut its full-year core revenue growth outlook. The company cut the upper end of its core revenue growth outlook range to 4% from 6% for the year, and maintained the lower end at 3%, primarily to take into account the effects of the weaker respiratory testing revenue. These trends overshadowed the improving trends in the life sciences tools market in a backdrop where pharmaceutical and biotech companies are in a race to increase research and manufacturing spending after the slowdown following the pandemic.
Following the earnings, BofA told investors that while the overall total company numbers were “fine” and ahead of expectations, the result “was certainly messier than expected”, driven primarily by a miss in bioprocessing that caused the stock to tumble 11%. While the firm maintained a Buy rating on Danaher Corporation (NYSE:DHR), it cut the price target on the stock to $230 from $270, stating that the company now has to rebuild confidence in the execution and business. This holds especially true as “this is not the first setback/headwind to pop up in recent years” for the company.
The stock is currently trading at a forward P/E of 22.51 at a 16.09% difference to the sector, which suggests that investors are paying a premium valuation. However, according to Insider Monkey’s extensive database tracking 1,022 hedge funds, Danaher Corporation’s (NYSE:DHR) hedge fund ownership dropped from 125 in fiscal Q4 2025 to 110 in fiscal Q1 2026. The total dollar value also dropped from $11.42 billion to $10.11 billion, suggesting that some institutional investors have become more cautious amid the company’s recent execution challenges.
What Investors Should Watch Next
Some prominent points of focus for investors could be bioprocessing order growth, and if revenues begin flowing into next year as management expects, investor confidence could improve significantly. Furthermore, management now expects 3%-4% core revenue growth for FY2026, and investors should monitor whether Danaher Corporation (NYSE:DHR) can meet or exceed those expectations. Sustained momentum and execution in the life sciences segment could also offset weakness elsewhere in the portfolio for the company.
Investors should also continue to watch end-market recovery and traction from Danaher Corporation’s (NYSE:DHR) recent growth initiatives, and they can support its expectation to end 2026 at a mid-single-digit core revenue growth rate. These factors can position Danaher Corporation (NYSE:DHR) to create sustainable and long-term shareholder value and accelerate the move of customers from discovery to delivery.
For the upcoming quarter, Danaher Corporation (NYSE:DHR) expects non-GAAP core revenue to increase in the 2.0% to 3.0% range year-over-year. It has similar growth expectations for the full year 2026, and anticipates non-GAAP core revenue to increase in the 3.0% to 4.0% range year-over-year.
Furthermore, Danaher Corporation (NYSE:DHR) raised its full-year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 compared to previous guidance of $8.35 to $8.55, reflecting continued optimism in its growth trajectory. Factors such as strong fiscal Q2 earnings performance and an earlier-than-expected completion of the Masimo acquisition further supported this guidance increase for the company. If the strong earnings performance persists, Danaher Corporation (NYSE:DHR) could be well-positioned to maintain its growth trajectory.
While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
